NCMAG105 Trastuzumab advice document: January 2023
Posted on:
Document Type
Process guidance
Summary
The treatment duration of 6-months, or 9 cycles, for adult patients categorised as lower risk with human epidermal growth factor receptor 2 (HER2) positive early breast cancer (EBC) in the neo-adjuvant and adjuvant treatment pathways. (Off-label use)